Oncology Revenue Cycle in 2026: How Drug Cost Inflation Is Reshaping Reimbursement Strategies
The oncology revenue cycle in 2026 looks very different than it did just a few years ago.
Rising drug acquisition costs, tighter payer scrutiny, evolving Medicare reimbursement rules, and growing prior authorization requirements have created a high-risk financial environment for oncology practices. With specialty drugs accounting for the majority of oncology revenue, even small reimbursement gaps can translate into significant losses.
Chemotherapy & Infusion Coding Errors That Delay Oncology Reimbursements
How Everest A/R Management Group Helps Oncology Practices Recover High-Dollar Claims Faster
Chemotherapy and infusion services drive a large share of oncology revenue—but they also carry the highest denial and delay risk in medical billing.
At Everest A/R Management Group, we consistently see oncology practices losing 15–35% of expected revenue due to avoidable chemotherapy and infusion coding errors.
Below are the most common issues—and how Everest fixes them.